5 news items
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
ALGS
5 Jun 24
Title: In vitro and in vivo pharmacological characterization of human PNPLA3-targeting short interfering
Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
ALGS
22 May 24
pharmacological characterization of human PNPLA3-targeting short interfering RNA molecules for the treatment of metabolic dysfunction-associated
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
ALGS
7 May 24
-dependent pharmacodynamic effects on atherogenic lipids and sex hormone binding globulin (SHBG), an indicator of target engagement in the liver
Aligos Therapeutics Presents Clinical Data At APASL 2024 From ALG-055009 And ALG-000184 Phase 1 Studies
ALGS
27 Mar 24
lipids and sex hormone binding globulin (SHBG), an indicator of target engagement in the liver.
The three oral presentations provide interim data
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
ALGS
27 Mar 24
on atherogenic lipids and sex hormone binding globulin (SHBG), an indicator of target engagement in the liver. The three oral presentations provide interim
- Prev
- 1
- Next